What Are the Challenges in Targeting Promoter Hypermethylation for Cancer Therapy?
While targeting promoter hypermethylation holds promise, several challenges exist:
Specificity: DNMT inhibitors can affect the methylation of both tumor suppressor and other genes, potentially leading to unintended side effects. Resistance: Cancer cells may develop resistance to these drugs, limiting their long-term efficacy. Delivery: Efficiently delivering DNMT inhibitors to the tumor site while minimizing systemic toxicity remains a significant hurdle.
